Zoom is expected to report an EPS of $1.48 and revenue of approximately $1.23 billion for the quarter.The company projects a 4% revenue increase, driven by AI expansion and strategic partnerships.Zoom's non-GAAP operating margin is anticipated to be 38.9%, indicating strong operational efficiency.Zoom Video Communications (NASDAQ:ZM) is gearing up to release its quarterly earnings on February 25, 2026. Analysts expect the company to report earnings per share (EPS) of $1.48, with revenue projected to reach a ...

Trueblue (NYSE:TBI) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsCarl Schweihs - EVP and CFOJessica Loos - Equity Research AssociateTaryn Owen - President and CEOConference Call ParticipantsMarc Riddick - Senior Equity AnalystMark Marcon - Senior Research Analyst covering Human Capital Technology & SolutionsOperatorGreetings, and welcome to the TrueBlue fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will f ...

Financial Data and Key Metrics Changes - Revenue in the fiscal third quarter of 2026 was a record $15.9 million, with an operating loss of $153,000 compared to an operating loss of $1.6 million in the same year-ago quarter, indicating significant improvement driven by higher advertising revenue and operational efficiencies [8][9] - Net loss for the quarter was $154,000 or -$0.01 per share, compared to a net loss of $1.6 million or -$0.06 per share in the year-ago quarter [8] - Adjusted EBITDA for the quarter was a record $2.8 million, compared to -$670,000 in the same year-ago quarter, reflecting revenue growth and disciplined cost management [8] Business Line Data and Key Metrics Changes - PodRoll revenue increased more than 5% quarter-over-quarter, reflecting growing adoption of the dynamic ad marketplace by brands and agencies [7] - The Dr. Gundry Podcast and The Adam Carolla Show were highlighted as standout performers, with significant audience engagement and renewed multi-year agreements [6][5] Market Data and Key Metrics Changes - The partnership with Dr. Phil's Envoy Media Company is expected to expand PodcastOne's reach into multi-platform owned media, enhancing its market position [5] - The company continues to see strong advertiser interest, particularly from major brands like Amazon and Progressive, indicating robust growth in media spending [65] Company Strategy and Development Direction - PodcastOne is focused on strategic partnerships, talent renewals, and expanding its owned and original content network, positioning itself as a leading content network rather than just a podcast publisher [4][10] - The company is leveraging AI-powered infrastructure to enhance operational efficiencies and audience engagement, which is expected to drive future growth [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing the company's strong position for continued growth throughout fiscal 2026 and beyond, driven by compelling content and strategic monetization [10] - The typical slowdown in advertising spending during the first quarter of the calendar year was acknowledged, with expectations to outperform last year's quarter despite a deceleration in guidance [53][54] Other Important Information - The company ended the quarter with $3.4 million in cash and cash equivalents and no debt on the balance sheet, indicating a strong financial position [9] - The acquisition of Varnamtown by Paramount for development as a streaming project underscores the strength of PodcastOne's original IP [7] Q&A Session Summary Question: What are the streams and downloads for Dr. Phil's podcast, and what has been the advertiser response? - Management noted excitement about the Dr. Phil relationship, with positive advertiser interest and plans for future projects [13][15] Question: How are B2B deals impacting current results and future outlook? - The Amazon ART19 deal was highlighted as a significant contributor to revenue and operational efficiencies, with expectations for continued growth in B2B relationships [18][19] Question: What is the outlook for cost of sales and G&A expenses? - Management indicated that G&A expenses are expected to remain stable in the short term, with ongoing efforts to improve cost efficiencies [44][45] Question: What is the talent environment like for acquiring new shows? - The competitive landscape for talent acquisition remains, but management is optimistic about ongoing relationships and new opportunities [60][63] Question: How is advertiser spending trending in the industry? - Management reported increasing media spending levels, with major brands shifting their budgets to podcasting, indicating a robust growth outlook [65]

Core Insights - The company is poised for growth driven by federal student lending reforms, particularly in the graduate lending segment, which is expected to present a $5 billion opportunity over the next two to three years as new rules take effect [1][3][7]. Growth Outlook - The company anticipates a year-over-year growth of 12% to 14% in private loan originations by 2026, with the impact of Grad PLUS reforms expected to begin influencing results during the peak season this year [2][7]. - The management views mid-single digit origination growth as a normalized run rate, with the current guidance reflecting incremental volume from program changes [7]. Strategic Partnerships - The company is implementing a strategic partnership funding model, starting with KKR, to enhance capital efficiency and generate fee-based income while expanding into new market segments [4][6][11]. - The partnership model is designed to create a long-term source of income while maintaining customer relationships through loan servicing [11]. Financial Projections - Operating expenses are projected to increase by approximately 16% year-over-year as the company invests in graduate product development and marketing, with initial marketing efforts expected to be inefficient [5][14]. - The loan portfolio is expected to remain flat to slightly decrease in the near term, with a return to modest growth anticipated later [6][8]. Market Position - The company leverages its established presence in undergraduate lending, including a significant sales force and relationships with over 2,100 schools, to compete effectively in the graduate lending market [15]. - The company has repurchased over 55% of its shares in the last five years and has announced a $500 million share repurchase authorization for the next two years, indicating confidence in its growth strategy [16]. Economic and Credit Performance - The partnership model is expected to be economically superior to traditional loan holding, with a focus on fee-based income and stable credit performance projected for 2026 [11][13]. - The company anticipates that the graduate cohort will exhibit higher credit quality and shorter duration compared to the core undergraduate product, potentially leading to lower reserve requirements [13]. Labor Market Insights - The company has noted a modest increase in new college graduate unemployment and a longer job search duration, but does not see significant negative impacts on borrower repayment performance from the resumption of federal student loan payments [20][21].

Core Insights - Rackspace Technology has appointed Joseph Vito as Senior Vice President of Strategic Alliance Partnerships to enhance its global strategy for technology and channel partnerships [1][3] - Vito has over 25 years of experience in technology leadership and cloud transformation, previously working with Amazon Web Services (AWS) and Dell-EMC [2][3] - The CEO of Rackspace, Gajen Kandiah, emphasized Vito's expertise in cloud transformation and strategic partnerships as crucial for advancing the company's mission to deliver scalable AI-enabled cloud environments [3] Company Overview - Rackspace Technology is recognized as a leading end-to-end hybrid cloud and AI solutions provider, capable of designing, building, and operating cloud environments across various technology platforms [5] - The company partners with clients throughout their cloud journey, facilitating application modernization, new product development, and the adoption of innovative technologies [5]

Core Insights - Ascent Solar Technologies has made significant commercial progress and formed industry partnerships in 2025, positioning itself for continued growth in 2026 [1][2] Company Achievements - The company has established new strategic partnerships with various organizations, including NovaSpark and Emtel Energy, to achieve commercial goals in the defense industry [6] - Ascent Solar has closed a private placement of up to $5.5 million to support its initiatives [6] - The company is advancing its thin-film photovoltaic (PV) product capabilities, including enhancements for space-based applications and marine durability [6] Market Positioning - Ascent Solar's thin-film solar products are designed to meet the increasing demand from the defense industry for efficient and readily available technologies [2] - The company aims to maintain momentum by engaging with potential partners and achieving greater efficiency milestones throughout 2026 [2] Production and Development - The company has initiated an aggressive production schedule to fulfill existing orders for array deployments planned for Q1 2026 [6] - Ascent Solar is developing UAV arrays for European partners in the first half of the year, showcasing its commitment to international collaboration [6] Research and Innovation - The company is conducting advanced environmental testing to quantify the performance of its products in extreme conditions, including radiation and atomic oxygen resilience [6] - Ascent Solar is partnering with the Georgia Institute of Technology to apply thin-film technology to UAV wings, aiming for continuous flight capabilities for ocean monitoring [6]

Core Insights - Bayer AG's shares rose by 6.6% following Orion's projection that long-term annual net sales from Nubeqa could exceed €1 billion, based on collaborative scenario planning [1][7] Group 1: Product Performance and Strategic Priorities - Nubeqa, developed jointly by Bayer and Orion, is approved for various prostate cancer indications in the U.S. [2] - Bayer outlined its strategic priorities for the Pharmaceuticals Division at the J.P. Morgan Healthcare Conference, emphasizing the strong performance of Nubeqa and Kerendia, which are offsetting declining sales of Xarelto [3][4] - Bayer's stock surged 126% over the past year, significantly outperforming the industry growth of 22.7% [4] Group 2: Future Growth Drivers - Bayer is focusing on new drug launches such as Beyonttra, Lynkuet, and asundexian to drive future growth [5][7] - Kerendia received FDA approval for expanded use in heart failure patients, becoming the only non-steroidal mineralocorticoid receptor antagonist approved for chronic kidney disease associated with type 2 diabetes [8] - Asundexian, an investigational oral Factor XIa inhibitor, has shown promising results in late-stage studies and is viewed as a potential blockbuster opportunity [10] Group 3: Oncology and Women's Health Developments - Nubeqa continues to show strong global uptake, with additional phase III readouts expected to extend its use [14] - The FDA approved elinzanetant for menopause-related symptoms, marking a significant boost for Bayer's women's health portfolio [17] - Bayer's pipeline includes advancements in cell therapy and gene therapy, with ongoing developments in treatments for Parkinson's disease and late-onset Pompe disease [18][19] Group 4: Overall Business Outlook - Bayer's pharmaceutical business is entering a new growth phase, supported by key revenue drivers, multiple late-stage catalysts, and a robust pipeline [20]

Core Insights - Realty Income (O) has formed a strategic partnership with GIC to establish a programmatic joint venture focused on developing high-quality logistics real estate in the U.S. [1][8] - The joint venture will have over $1.5 billion in combined capital commitments, with Realty Income holding a majority ownership of the purchased assets [2][8] - The partnership includes a $200 million commitment to expand Realty Income's presence in Mexico, involving construction financing and a takeout purchase for an industrial portfolio [2][8] Strategic Initiatives - The joint venture aims to broaden funding sources beyond public capital markets and enhance investment opportunities for long-term returns [3] - Realty Income is also diversifying into alternative assets, including investments in gaming properties and data centers, to capture long-term growth [4] Industry Comparisons - Other retail REITs, such as Simon Property Group and Kimco Realty, are also pursuing growth through acquisitions and redevelopments, indicating a competitive landscape [5][6] Financial Performance - Realty Income's shares have increased by 0.4% over the past six months, lagging behind the industry average increase of 3.5% [7] - The company trades at a forward 12-month price-to-FFO of 13.31, which is below the industry average but close to its one-year median of 13.22 [9] Earnings Estimates - The Zacks Consensus Estimate for Realty Income's 2025 FFO per share has been revised downward, while the estimate for 2026 has been adjusted upward [10]

Financial Data and Key Metrics Changes - The company reported a projected net revenue of $395 million for 2025, with 65% of that revenue expected to come from wholesale channels, indicating a deliberate diversification strategy [29] - The company has experienced significant cost inflation, particularly in green coffee prices, which have doubled over the last two years due to adverse weather conditions and tariffs [32][34] - The company aims to restore gross margins to 40% over time through pricing actions, productivity improvements, and a shift towards more profitable wholesale business [36] Business Line Data and Key Metrics Changes - The core coffee business remains the primary revenue driver, with significant growth in ready-to-drink (RTD) coffee, which is now the third-largest in America [21][24] - The company is focusing on innovation in the RTD coffee category, with new products like Cold Brew set to launch in January [25] - The energy segment is being reevaluated for strategic distribution, with plans to focus on areas where the company has previously seen success [28] Market Data and Key Metrics Changes - The company has diversified its customer base from 90% direct-to-consumer in 2019 to a more balanced approach with significant retail partnerships, including Walmart and Kroger [29] - The company is now present in 55% of measurable grocery and mass stores across the country, indicating a successful land and expand strategy [24] Company Strategy and Development Direction - The company emphasizes its mission-driven narrative and veteran-backed identity as a strategic advantage in the marketplace [10][11] - The focus is on building brand momentum and community engagement through social media and partnerships with influential figures [12][17] - The company aims to maintain investment in its core coffee business while exploring adjacent markets like energy and RTD coffee [21][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by rising coffee prices and inflation but remains confident in the company's ability to navigate these issues through strategic execution [32][34] - The management team is committed to building credibility and consistency over the next two years, focusing on delivering results and capitalizing on growth opportunities [11][36] Other Important Information - The company has reduced headcount by nearly 50% from its peak in 2022 as part of restructuring efforts to streamline operations [35] - The management team consists of military veterans, which is highlighted as a key aspect of the company's identity and operational philosophy [1][3] Q&A Session Summary Question: What is the company's strategy for the energy segment? - The company plans to focus on specific geographies where it has previously seen success and will not attempt to expand nationwide without adequate support [28] Question: How does the company plan to address cost inflation? - The company will pursue pricing actions, improve productivity, and shift its business mix towards more profitable wholesale channels to manage cost inflation [32][34]

Core Viewpoint - PharmaTher Holdings Ltd. is positioned for significant value creation in 2026 following a year of strategic execution and validation in 2025, focusing on asset monetization and strategic partnerships to enhance revenue and equity value [2][5][16]. Group 1: 2025 Achievements - The company achieved FDA approval for its Ketamine ANDA (217858), marking a pivotal moment that enhances drug development and regulatory confidence [6]. - The sale of the U.S. Ketamine ANDA was completed in December, with potential earnings exceeding US$25 million through an asset purchase agreement that includes upfront payments, sales-based milestones, and profit-sharing [7]. - PharmaTher advanced its asset-driven platform by offering KetaVault™ and KetAImine™, aimed at enabling commercial partnerships [8]. - An Exclusive Evaluation and Option-to-License Agreement was secured with Oakwood Laboratories for a patented long-acting injectable ketamine program targeting neuropsychiatric indications [9]. Group 2: 2026 Objectives - The company plans to realize the economic benefits from the Ketamine ANDA sale, which includes upfront proceeds and profit-sharing tied to cumulative sales [11]. - International expansion for ketamine is a priority, with plans to pursue regulatory and commercial initiatives across multiple geographies [12]. - Strategic partnerships will be sought for ketamine programs, particularly in Parkinson's disease and drug delivery, to improve capital efficiency and accelerate development [13]. - The company aims to crystallize the value of its 49% equity interest in Sairiyo Therapeutics Inc. through various potential transactions [14]. - Development of a next-generation ketamine product will continue, focusing on long-acting injectable formulations and assessing both internal and external opportunities [15]. Group 3: Overall Strategy - PharmaTher's strategy emphasizes acquiring and advancing assets that can be efficiently monetized to generate product revenue, royalty income, and equity value [3][19]. - The company is committed to non-dilutive value creation through disciplined cost control, having reduced cash burn and maintained a lean organization [4].